trending Market Intelligence /marketintelligence/en/news-insights/trending/uipsifti88vxvtviijjsoq2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Tonix Pharmaceuticals shares plunge as company terminates PTSD drug trial

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Tonix Pharmaceuticals shares plunge as company terminates PTSD drug trial

Tonix Pharmaceuticals Holding Corp. stocks tumbled after the company said it was terminating a late-stage study of its drug Tonmya for the treatment of military-related post-traumatic stress disorder.

The New York-based company's stock plunged 66.84% to $1.31 per share as of 11:19 a.m. ET on July 27.

The company was studying the medicine in a phase 3 study dubbed Honor, which enrolled 550 patients. An independent review of a portion of the trial results showed the drug was not better than placebo in improving PTSD symptoms after 12 weeks of treatment — the primary goal of the study.

Tonmya, also called TNX-102, is an under-the-tongue formulation of cyclobenzaprine, commonly used as a muscle relaxer.

The company is not completely scrapping the program, however, hoping to use data from the four-week cutoff to design a new study.

After four weeks of treatment, patients saw an improvement in their symptoms, including in measures related to sleep.

"We plan to meet with the [U.S. Food and Drug Administration] as soon as possible to discuss the Honor results and our proposal to conduct the primary analysis at the week-4 time point in the next pivotal study," Tonix Pharmaceuticals President and CEO Seth Lederman said in a statement.

"These results underscore the challenges in designing and conducting well-controlled clinical studies in PTSD, especially military-related PTSD," Lederman added.

About 11 million adults in the U.S. have PTSD.